We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tiotropium for chronic obstructive pulmonary disease.
- Abstract
In 2001, we concluded that patients with symptoms of stable chronic obstructive pulmonary disease (COPD) inadequately controlled by an 'as-required' inhaled short-acting beta 2 agonist can be helped by regular use of an inhaled antimuscarinic bronchodilator or a long-acting beta 2 agonist. Since then, a new antimuscarinic drug [symbol: see text] tiotropium bromide (Spiriva--Pfizer/Boehringer Ingelheim) has been licensed as a once-daily bronchodilator for maintenance treatment of COPD in people aged 18 years or over. Here, we review the evidence for efficacy of tiotropium and discuss its role in the maintenance treatment of COPD.
- Publication
Drug and therapeutics bulletin, 2003, Vol 41, Issue 2, p15
- ISSN
0012-6543
- Publication type
Journal Article
- DOI
10.1136/dtb.2003.41215